Thursday's rally was sparked by news that Moderna's Covid-19 vaccine candidate is moving to Phase II testing.
The charts and indicators of ARE are heading in the right direction but not with convincing volume.
CEO McMullen said it's not a matter of if they'll have a vaccine, but when.
The drugmaker that is partnering with Sanofi to develop a vaccine has seen its shares push higher after declining to a low in late March.
With a strong history in an important industry, Becton Dickinson looks set to provide and increase its dividend through this crisis and beyond.
The technical signals for the technology provider to the life science industry show its shares have upside potential.
The next four to six weeks could determine whether the U.S. economy can recover from the coronavirus crisis without lasting damage
The pace of the selloff in shares of the maker of lab equipment has begun to slow and that is a positive.
The technology giant has been in bearish mode for quite some time and likely will need to rebase before the coast is clear to buy it.
The stock of the medical device maker has been stagnant for months and its charts have yet to prove themselves.